Andrea Paul

All filings by Andrea Paul on record concern Zentalis Pharmaceuticals, Inc. We count 5 filings; the first trade dates from 1 February 2023 and the latest from 3 February 2025.

No open-market purchase appears, only 2 sales worth €57k. The rest of the record consists of 3 share grants. Since January 2025: no purchases and 1 sale on the market.

The record was last updated on 5 February 2025 with an open-market sale (€22k) in Zentalis Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.